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Abstract
The high affinity IgE receptor, FceRI, plays a key role in the immunological pathways involved in allergic asthma. Previously
we have demonstrated that human neutrophils isolated from allergic asthmatics express a functional FceRI, and therefore it
was of importance to examine the factors regulating its expression. In this study, we found that neutrophils from allergic
asthmatics showed increased expression of FceRI-a chain surface protein, total protein and mRNA compared with those
from allergic non asthmatics and healthy donors (p,0.001). Interestingly, in neutrophils isolated from allergic asthmatics,
FceRI-a chain surface protein and mRNA expression were significantly greater during the pollen season than outside the
pollen season (n=9, P=0.001), an effect which was not observed either in the allergic non asthmatic group or the healthy
donors (p.0.05). Allergen exposure did not affect other surface markers of neutrophils such as CD16/FccRIII or IL-17R. In
contrast to stimulation with IgE, neutrophils incubated with TH2 cytokines IL-9, GM-CSF, and IL-4, showed enhanced FceRI-a
chain surface expression. In conclusion, these results suggest that enhanced FceRI expression in human neutrophils from
allergic asthmatics during the pollen season can make them more susceptible to the biological effects of IgE, providing a
possible new mechanism by which neutrophils contribute to allergic asthma.
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Introduction
Asthma is a chronic inflammatory disease of the bronchial
airways which has been increasing in prevalence during the last
four decades. Airway inflammation is a major factor in the
pathogenesis of asthma, in associated bronchial hyperresponsive-
ness and in disease severity [1,2]. The inflammatory component of
this disease includes an increased number of activated T
lymphocytes, mast cells, neutrophils and eosinophils within the
airway lumen and bronchial submucosa [3].
Many studies support the concept that neutrophils may
significantly contribute to chronic inflammation and alterations in
airwaystructurethatcharacterizeasthma.Afterallergenchallengeof
patients with allergic asthma, neutrophils are the first inflammatory
cells to accumulate within the airways and neutrophil numbers in
bronchoalveolar lavage (BAL) fluid of patients with allergic asthma
after allergen challenge have been calculated to be about 90 times
higher than healthy controls [4,5,6]. Furthermore, an increase of
airway neutrophils was also detected in induced sputum from adults
with acute exacerbations of severe asthma, and in bronchial biopsies
of severe steroid resistant asthmatics [7,8,9]. Circulating neutrophils
are activated during active asthma, after exercise-induced broncho-
spasm and during both earlyand late asthmatic reactions induced by
allergen [7].
IgE has long been regarded as a major molecular component of
atopic diseases, including asthma [10]. Clinical studies have found
a close association between allergic asthma and elevated serum
specific IgE levels as well as IgE dependent skin test reactivity to
allergens [11]. In addition, allergen specific IgE has been detected
in bronchoalveolar lavage fluids in asthmatic patients [12].
The high affinity receptor for IgE (FceRI) is a key structure
involved in immediate allergic manifestations [13]. Initially
discovered on mast cells and basophils whose function is to
mediate cellular degranulation and the release of various
mediators such as histamine [13], FceRI has been later detected
on many inflammatory cells including human cutaneous Langer-
hans cells, dendritic cells, monocytes of patients with a number of
allergic disorders, on eosinophils from subjects with hypereosino-
philic syndrome or asthma, on platelets, and bronchial epithelial
cells [14,15,16,17,18].
Recently, we demonstrated that human neutrophils isolated
from allergic asthmatics express FceRI [19] and thus, it was of
importance to examine the factors regulating expression of FceRI
in human neutrophils. Here, we show that human neutrophils
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with allergic non asthmatics and healthy donors. Furthermore,
natural seasonal allergen exposure up-regulates FceRI expression
at mRNA and cell surface levels in neutrophils of allergic
asthmatics but not in allergic non asthmatics or healthy donors.
This effect is selective since seasonal allergen exposure did not alter
surface markers of neutrophil such as FccRIII/CD16. Interest-
ingly, in vitro stimulation with TH-2 cytokines including IL-9, GM-
CSF and IL-4 induced elevated FceRI expression in neutrophils
from allergic asthmatics.
Results
Increased expression of FceRI in human neutrophils from
allergic asthmatics compared to non asthmatic allergic
and healthy individuals
Expression of FceRI by cells other than mast cells was
previously reported, as was expression in neutrophils [19]. To
investigate the level of FceRI expression in human neutrophils
from allergic asthmatic, allergic non asthmatic and healthy
individuals, we first analyzed FceRI mRNA expression by
fluorescent in situ hybridization (FISH) using anti-sense FceRI-a
chain riboprobe. Neutrophils from allergic asthmatics showed an
increase in FceRI mRNA expression (mean percentage of positive
cells 63.2610.21%, n=19) compared with allergic non asthmatic
(22.968.08%, n=18) or healthy individuals (10.1466.25 %,
n=21) (p,0.001, Figure 1A, B). No specific signal could be
detected with sense riboprobe used as negative control (data not
shown). Furthermore, real-time RT-PCR analysis showed a
significant increase of FceRIa chain mRNA in neutrophils from
allergic asthmatics (n=7) compared with healthy individuals
(n=10, p=0.0046), but not allergic non asthmatics (n=6,
p.0.05, Figure 1F). Moreover, neutrophils from allergic asthmat-
ics express 1000 to 300 times less FceRI-a mRNA compared to
basophilic cell line KU812 (relative mean copy number in
KU812=7376134/GAPDH copy, n=3).
To confirm that neutrophils from allergic asthmatics expressed
FceRI at cell surface, flow cytometry analysis using mAb directed
against the FceRI a chain, the IgE binding subunit [20], was
performed. Neutrophils from allergic asthmatics, which express the
neutrophil marker CD16 (Figure 1E), showed an increase in FceRI
surface expression (% of positive cells 47.6765.46%; Mean
fluorescence intensity (MFI)=49.5612.37, n=17) compared with
neutrophils from allergic non asthmatics (7.7464.41%; MFI=
3.5462.3; n=15) and healthy individuals (6.2363.39%;
MFI=0.6560.3; n=16) (p,0.001, Figure 1C, D). Interestingly,
we found that neutrophilsexpress between 1.3to 10 times less FceRI
surfacereceptorcomparedwithbasophiliccellline(KU812)byusing
quantitativeindirectimmunofluorescence (Supplemental Figure 1B).
We further analyzed the same samples by immuno-fluorescence and
found an increase in FceRI protein expression in neutrophils from
allergic asthmatics (% of positive cells: 86.9269.03 %; n=10)
compared with allergic non asthmatics (28.82613.47%; n=11) and
healthy donors (0.460.5; n=11).
Figure 1. Upregulated FceRI a chain mRNA and surface expression in neutrophils from allergic asthmatics. Neutrophils FceRI a chain
mRNA and surface expression in allergic asthmatics, allergic non asthmatics and healthy subjects were determined by FISH (A,B) real-time RT-PCR (F)
and flow cytometry (C, D), respectively, as described in Methods. E. FccRIII/CD16 surface expression on neutrophils of the same subjects in A and C. ,
*p,0.0001, **p,0.01, ns: non significant. P values were calculated using Mann Whitney U test. IC mAb: isotype control. Example of cells with positive
(one asterisk) and negative (two asterisks) signal in FISH are indicated in panel A.
doi:10.1371/journal.pone.0001921.g001
FceRI in Neutrophils
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FceRI expression by human neutrophils from allergic
asthmatics
We then investigated whether allergen exposure during the pollen
season can account for the increased expression of FceRI in human
neutrophils from allergic asthmatics. FceRI expression was tested in
and out of the pollen season in neutrophils from the same allergic
asthmatics, non allergic asthmatics and healthy donors. Flow
cytometry analysis of human neutrophils from allergic asthmatics
showed an increase in FceRI surface expression during the pollen
season (57.37618.7 during versus 18.8614.5 out of season, n=9,
P,0.001, Figure 2A, B). FISH and immunofluorescence analysis
revealed a similar pattern with an increase of FceRI a chain mRNA
positive neutrophils (Figure 2 C, D) and FceRI-a chain immuno-
positive neutrophils (data not shown) during the pollen season
compared with neutrophils obtained out of the pollen season.
To confirm that seasonal allergen exposure selectively affected
FceRI expression in neutrophils from allergic asthmatics, surface
expression of human neutrophil markers FccRIII/CD16 and IL-
17AR was investigated by FACS in neutrophils isolated from the
same allergic asthmatic subjects. As detected by FACS analysis
FccRIII/CD16 (Figure 2E–F) and IL-17R (data not shown)
expression was stable during and out of the pollen season
(p.0.05). Furthermore, seasonal allergen exposure did not affect
FceRI surface or mRNA expression by human neutrophils from
allergic non asthmatics and healthy individuals (p.0.05, Figure 2B
and D).
Effect of TH-2 cytokines on FceRI expression in
neutrophils from allergic asthmatics
To investigate the potential mechanism through which seasonal
allergen exposure might influence FceRI expression in human
Figure 2. Effect of pollen season on surface and mRNA expression of FceRI in human neutrophils. FceRI a chain surface (A, B) and mRNA
expression (C, D) are up-regulated during the pollen season in human neutrophils from allergic asthmatics, but not in allergic non asthmatics or
healthy donors. *p,0.01, ns: non significant. P values were calculated using Wilcoxon signed rank test. (E, F) represent CD16 surface expression in
neutrophils from the same subjects as in (A, B) and (C–D).
doi:10.1371/journal.pone.0001921.g002
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cytokines on FceRI expression in vitro. Expression of FceRI mRNA
and protein was analyzed following stimulation with IL-4, IL-9 or
GM-CSF for 6hr. The number of FceRI-a chain mRNA copies
was consistently higher in IL-9 or GM-CSF stimulated cells than
in unstimulated neutrophils, as measured by real-time RT-PCR in
three separate experiments (Figure 3). Although IL-4 seems to
enhance FceRI a chain mRNA expression in human neutrophils it
did not reach significance (p.0.05). Moreover, stimulation with
IFN-c decreased the expression of FceRI mRNA in neutrophils
from allergic asthmatics (n=3, P,0.05, Figure 3). We then
confirmed the effect of TH-2 cytokines on FceRI expression at the
surface and intracellular protein level. As detected by flow
cytometry, IL-4, GM-CSF and IL-9 up-regulated significantly
FceRI a chain surface expression in human neutrophils from
allergic asthmatic individuals (n=4, p,0.05, Figure 4A and B).
Furthermore, in contrast to medium treated cells, significant up-
regulation of FceRI-a chain 45,48 kDa was detected in IL-9, IL-
4 and GM-CSF stimulated neutrophils as detected by immuno-
precipitation with IgE/anti IgE and Western blot using anti-FceRI
a chain mAb (Figure 4C, n=3).
Discussion
IgE has long been regarded as a major molecular component of
allergic diseases, including asthma[10]. The effect of IgE is
amplified by the activities of the receptors to which it binds. The
high affinity receptor for IgE (FceRI) is a key structure involved in
immediate allergic manifestations. Recently, it has become
apparent that neutrophils from allergic asthmatics express FceRI
[19]. Although this reveals the capability of these cells to respond
to stimuli considered integral to the allergic process, factors that
modulate FceRI expression by human neutrophils have not been
investigated. In our study, we have demonstrated that neutrophils
from allergic asthmatics have increased FceRI expression
compared with healthy donors or allergic non asthmatics.
Interestingly, seasonal allergen exposure selectively enhances the
surface and mRNA expression of FceRI in human neutrophils
from allergic asthmatics and not in allergic non asthmatics or
healthy donors. Furthermore, neutrophils from all groups showed
no change in surface expression of CD16/FccRIII and IL-17R
during and out of pollen season. Moreover, TH-2 cytokines, highly
expressed in human allergic asthma, mimicked seasonal pollen
exposure in vitro and up-regulated FceRI expression in neutrophils
from allergic asthmatics (Figure 3 and 4) but not from allergic non
asthmatics or healthy donors (data not shown). Taken together,
our data provide a potential new mechanistic explanation of
increased neutrophil presence and activity in allergic asthma [21].
Figure 3. TH-2 cytokines up-regulate FceRI a mRNA expression
in human neutrophils isolated from allergic asthmatics.
Neutrophils from three different asthmatics stimulated with IL-9, IL-4,
or GM-CSF (10ng/ml) for 6h showed increased mRNA expression of
FceRI a chain as determined by Real-time RT-PCR. Data represents the
mean6SEM of three independent experiments performed under the
same condition. * P,0.05 compared with medium alone and were
calculated using Mann Whitney U test.
doi:10.1371/journal.pone.0001921.g003
Figure 4. TH-2 cytokines induce FceRI a chain surface expression in neutrophils from allergic asthmatics. A. Representative FACS data
of FceRI a chain surface expression in neutrophil stimulated with IL-9, IL-4, or GM-CSF (all at 10ng/ml) for 18hrs. FACS was performed using mAb anti-
FceRI a chain (CRA-1). B. Each point represents mean6SEM values from four allergic asthmatic donors. Results are expressed as MFI of CRA-1 minus
MFI of isotype control mAb (DMFI). * P,0.05 compared with with medium alone and were calculated using Mann Whitney U test. (C) Total protein
lysates were subjected to immunoprecipitation with IgE/anti IgE and Western blotting with CRA-1 as described in Methods. Basophilic cell line
(KU812) was used as positive control. Negative control corresponds to neutrophil protein lysate analyzed without IgE/anti-IgE immunoprecipitation.
Data in C is representative of three separate experiments.
doi:10.1371/journal.pone.0001921.g004
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on mast cells and basophils which mediate cellular degranulation
and the release of various mediators such as histamine,
leukotrienes and a number of cytokines and chemokines, the
hallmark of allergic reactions [13]. Later, FceRI was also detected
on human cutaneous Langerhans cells, monocytes from patients
with allergic disorders, eosinophils from patients with hypereosi-
nophilic syndrome or asthma, on platelets, circulating dendritic
cells and bronchial epithelial cells[13,18]. FceRI expressed on
monocytes and circulating dendritic cells was shown to mediate
calcium flux [15], and to promote IgE mediated antigen
presentation [16]. We assessed the expression of FceRI in human
neutrophils among the three groups of individuals in two ways.
First, we determined the mRNA expression of FceRI-a chain
using in situ hybridization. Second, we compared surface and total
protein expression of FceRI-a chain using flow cytometry and
immunofluorescence, respectively. These analyses showed that
neutrophils in allergic asthmatics but not in allergic non asthmatics
or healthy individuals expressed high levels of mRNA, surface and
intracellular protein FceRI. In accordance with our results, high
levels of FceRI expression have been observed in monocytes,
eosinophils and Langerhans cell from allergic subjects compared
with healthy donors [13]. Interestingly, heterogeneity in FceRI
expression is observed within neutrophils from allergic asthmatic
at the level of both mRNA and protein, suggesting that FceRI
expression in neutrophils is highly regulated.
We then investigated whether seasonal exposure to allergen
affects FceRI in neutrophils from the three groups. Our data
clearly demonstrated specific up-regulation of FceRI at the mRNA
and protein level in neutrophils isolated ex vivo during the pollen
season (Figure 2). Expression of other surface receptors by human
neutrophils was not affected, suggesting that FceRI may play a role
in allergic asthma during pollen season.
Studies that have investigated the regulation of FceRI in vivo and
in vitro, have shown a correlation between the serum IgE level and
FceRI expression on the cell surface [22,23]. Two hypotheses have
been proposed to explain the basis of this correlation. Either a
common factor was capable of regulating the level of both serum
IgE and IgE receptors, or the number of receptors was modulated
by serum IgE concentrations [24,25]. Subsequent studies have
demonstrated that monomeric IgE up-regulates FceRI expression
on human mast cells and mouse basophils [23,26,27]. The
proposed mechanism of this up regulation is that IgE protects the
cell bound receptors from degradation during receptor recycling
[13]. Mast cells from IgE deficient mice express low levels of FceRI
unless up-regulated by in vitro incubation of these cells with IgE or
injection of IgE in vivo [28]. However, our data revealed that in vitro
incubation with IgE has no effect on FceRI surface expression in
human neutrophils isolated from allergic asthmatic (Figure S1,A)
or allergic non asthmatic individuals (data not shown). This
phenomenon may occur through various plausible mechanisms.
First, stabilization by IgE, which prevents FceRI receptor
internalization and degradation, may not have occurred in
neutrophils, in contrast to human basophils [29,30]. Second, the
preformed pool of FceRI receptor was possibly not adequately
transported to the cell surface. Third, the basal level of FceRI
protein synthesis was not maintained in cultured neutrophils, due
to their well documented low transcriptional and translational
capacity, thus preventing intracellular pool and cell surface
replenishment. Fourth, it may be that IgE prevents FceRI surface
loss within 24 hrs of culture but simultaneous apoptosis occurring
in neutrophils with associating membrane changes may disguise
this effect. Further in depth studies are needed to address these
possibilities.
Regulation of FceRI expression is not entirely dependent on
IgE. Mast cells from IgE deficient mice express low levels of
FceRI [28] which suggests that the basal levels are under the
control of other regulators. In this study, we have clearly
demonstrated that Th-2 cytokines IL-9, GM-CSF and IL-4,
upregulate FceRI protein expression in human neutrophils.
These data are in agreement with a positive role of IL-4 and
IL-9 in the transcription of FceRI-a chain in human mast cells,
eosinophils from patients with atopic dermatitis and human
dendritic cells [31,32,33]. Interestingly, although IL-4 did
significantly increase FceRI surface expression in human
neutrophils it’s effect at mRNA level was not consistent which
may suggest that IL-4 affects FceRI expression by a different
mechanism than GM-CSF and IL-9. Furthermore, we also
demonstrated that GM-CSF upregulates FceRI in human
neutrophils (Figure 3). As a key cytokine with pleotropic activity
on neutrophil function, GM-CSF also has the ability to induce
other neutrophil surface receptors, including the low affinity IgE
receptor CD23/FceRII [34]. Taken together, our data highlight
the fact that Th-2 cytokines directly and indirectly account for
the pathophysiologic manifestations of allergy and are involved in
inducing FceRI, hence amplifying the IgE/ IgE receptors
network.
In previous studies, we and others have demonstrated that
FceRI dependent activation of neutrophils from allergic asthmatics
leads to IL-8 release [19,35], a potent neutrophilic chemoattrac-
tant, as well as proteases that may damage airway mucosa
[35,36,37]. More recently, we have demonstrated that IgE binding
to FceRI can enhance neutrophil survival in allergic asthmatics by
a mitochondrial dependent mechanism [21]. In light of these
studies and our present data, we propose that, in vivo, allergen
exposure in sensitized asthmatics not only enhances neutrophil
recruitment to the site of allergen exposure but also upregulates
expression of FceRI by these cells which may therefore participate
in IgE-mediated allergic inflammatory responses.
Methods
Subjects
This study was approved by the Ethics Committee of the
Faculty of Medicine, University of Manitoba, Winnipeg, Canada
and written informed consent was obtained from each participant.
In response to advertisements, individuals 18–45 years old were
recruited in each of three groups: allergic individuals with mild
asthma, allergic non-asthmatics, and healthy donors. The clinical
diagnosis of allergic asthma was determined by: (i) history of
asthma symptoms (wheeze, cough, and/or shortness of breath)
during the short (6–8 week long) local grass pollen season,
controlled with albuterol as needed; (ii) positive epicutaneous test
to mixed grass pollen (wheal diameter at least 3 mm more than
histamine control wheal) to an epicutaneous test with mixed grass
pollen; (iii) 15% or greater improvement in forced expiratory
volume in one second (FEV1) after inhalation of albuterol (200 mg)
from a metered-dose inhaler. The clinical designation of allergic
non-asthmatic was determined by: (i) history of allergic rhinitis
symptoms (sneezing, nasal itching, discharge, and/or congestion)
during the short local grass pollen season, relieved by an H1-
antihistamine as needed; (ii) positive epicutaneous test to mixed
grass pollen (wheal diameter at least 3 mm more than histamine
control wheal), (iii) no history of asthma symptoms at any time of
year, normal FEV1 and no change in FEV1 after albuterol 200 mg
from a metered-dose inhaler. The healthy donors had no history of
asthma, allergic rhinitis, or other allergic disease, negative
epicutaneous tests to mixed grass pollen, normal FEV1 and no
FceRI in Neutrophils
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Study participants had not received allergen-specific immunother-
apy. For three days before collection of a 40 ml blood sample, all
participants refrained from using all medications, including b2-
adrenergic agonists and H1-antihistamines. Participants who
reported an upper respiratory tract infection within the previous
month were excluded from the study.
Reagents and antibodies
FITC-conjugated AffiniPure rat anti-mouse IgG (H+L) and
F(ab)92 were obtained from Jackson ImmunoResearch Laborato-
ries (West-Grove, Pennsylvania). Monomeric IgE was purchased
from Diateck (Oslo, Norway). Murine anti-human IgE mAb was
purchased from BD Biosciences Pharmingen (Mississauga, On-
tario). Murine anti-FceRIa chain mAb CRA-1 (mouse IgG1)
which recognizes non IgE-binding site was kindly provided by Dr.
Chisei Ra, Tokyo University, Japan. FITC labelled mouse anti-
human CD16 mAb (Clone 3G8, IgG1), FITC labelled and
unlabeled mouse IgG1 isotype control mAb, (clone MOPC21,
IgG1) were obtained from Sigma Chemical Co. (Oakville,
Ontario). Anti-CD16 mAb immunomagnetic beads were obtained
from Miltenyi Biotec (Auburn, Calif). Recombinant human IL-9,
IL-4, GM-CSF, and IFN-c were purchased from R&D Systems
MN). LightCycler-DNA Master SYBR Green I, digoxigenin UTP,
and mouse monoclonal anti-digoxiginin were purchased from
Roche (Mississauga, Ontario). Ficoll-Paque
TM Plus and Dextran
500 were obtained from Amersham Pharmacia Biotech AB (Baie
d’Urfe ´, Quebec). HyQH RPMI 1640 and heat inactivated foetal
bovine serum were obtained from Hyclone Laboratories (Logan,
Utah). ProLongH antifade, propidium iodide, Tyramide Signal
Amplification Kit were obtained from (Invitrogen, Carlsabd, CA).
Unless stated otherwise, all other reagents were obtained from
Sigma Chemical Co.
Cell preparation and culture
Human neutrophils were purified from peripheral blood as we
described previously [19]. Viability of the cells was .98% as
assessed by trypan blue dye and purity ranged from 96 to 99%.
Freshly isolated neutrophils (2610
6/ml) from three allergic
asthmatic subjects were incubated at 37uC in humidified 5%
CO2 in RPMI 1640 medium supplemented with 10% heat
inactivated FBS and antibiotics for 6 or 18 hrs at 37uC with IL-9,
IL-4, GM-CSF, or IFN-c at a final concentration of 10ng/ml.
After culture, cells were washed and either stained for FceRI-a
chain surface protein or subjected to RNA isolation and protein
extraction for real time RT-PCR and Western blot analysis.
Cytospin slides were prepared from freshly isolated or cytokine
stimulated neutrophils as previously described [19].
Flow cytometry
Flow cytometry analysis was performed by incubating freshly
isolated or cytokine stimulated neutrophils (1610
5) cells for 30 min
in PBS/5% FBS with mAb CRA1 or isotype control mAb IgG2a
(final concentration 10 mg/ml) [19]. The cells were washed twice
with PBS/2%FBS and incubated for 30 min with affinity purified
FITC conjugated rat anti-mouse IgG F(ab)92 (1:200). After
washing, cells were fixed with 2% PAF and resuspended in
500 ml of PBS and analyzed on FACScan (Beckman-Coulter Inc.,
CA). The purity of the neutrophil preparation was also confirmed
by staining using FITC labelled anti-CD16 mAb or isotype control
IgG1 mAb(1/100 dilution). FACS analysis was done with
CellQuest Software (Beckman-Coulter Inc). The results are
presented as overlaid histograms and as percentage of positive
cells.
Quantitative indirect immunofluorescence test
Quantitative determination of FceRI a chain cell surface
expression in human neutrophils and basophilic cell line
(KU812) was performed using QIFIT as recommended by the
supplier (DakoCytomation, CA). Two beads were used in this
protocol. Setup beads were a mixture of blank and high
fluorescence beads that were used to establish the fluorescence
window of analysis of flow cytometer. The voltage of the
fluorescence detector (PMT) was adjusted to make sure that both
negative cells and the two populations of beads were displayed
simultaneously on the fluorescence scale. The calibration beads were
a mixture of beads with well-known numbers of antibody binding
sites per bead; fluorescence data corresponding to each of the five
bead peaks were used to construct the calibration curve of mean
fluorescence intensity (MFI) against binding capacity (ABC). Briefly,
neutrophils and KU812 (1610
5 /100 ml) were labelled under
saturating conditions with mAbCRA-1 or isotype IgG2a control
(10 mg/ml). After washing, cells and setup beads and calibration
beads were stained, in parallel, with affinity purified FITC
conjugated rat anti-mouse IgG F(ab)92 in saturating amounts
(1:200). Cells were analyzed on the flow cytometer and ABC was
calculated based on the equation of the calibration curve [38].
FISH
FceRI a chain probe was generated by RT-PCR and subcloned
into pBluescript vector (Stratagene, Mississauga, Ontario) [19].
Vector was linearized with the appropriate enzymes and
transcribed with digoxigenin UTP (Roche, Mississauga, Ontario)
to generate sense and anti-sense riboprobes as we described
previously [19]. For ISH procedures, slides were washed,
prehybridized with hybridization buffer (50% Formamide, 5X
SSC, 100 mg/ml Heparin, 1X- Denhardt’s solution, 0.1% Tween
20, 0.1% CHAPS, 5mM EDTA and 0.3mg/ml yeast tRNA),
followed by adding digoxigenin labeled anti-sense probe (1 mg/ml)
overnight at 42uC. Digoxigenin labelled sense probe was used as
negative control. The slides were washed three times with 0.2X
SSC for 30 min at 65uC and PBT (0.1% Triton X 100, 2 mg/ml
BSA, PBS) for 20 min at room temperature. After endogenous
peroxide activity blocking, the slides were washed with TNT
(0.1M Tris HCl pH7.5, 0.15M NaCl, 0.05% Tween 20) for 5min
each at RT, incubated with mouse monoclonal anti-digoxigenin
(1:100) for 30min at RT, followed by tyramide signal amplification
(TSA) step using HRP conjugated goat anti-mouse IgG (H+L) and
Alexa Fluor 488 tyramide as described by the manufacturer
(Invitrogen, Carlsabd, CA). TSA is an ultrasensitive molecular
morphology detection technique that utilizes the catalytic activity
of horseradish peroxidase to generate robust labeling of target
nucleic acid sequence or protein in situ in tissue sections or on cells
in suspension [39]. Counterstaining was performed with propidium
iodide. After washing with PBS, the slides were mounted with
ProLongH antifade. Images were acquired under oil immersion at
100x magnification by confocal laser scanning microscopy
(Olympus IX70 inverted microscope coupled to FluoVIEW
confocal laser scanning system with a Cooke Sensicam (Olympus
America Inc., Melville, NY). The value of ISH represents the
percentage of cells that had a clear signal compared to background
signal obtained with the sense probe. This was determined by
counting the positive and negative cells, blindfolded for subjects
and is the average of three different counts by two different
individuals. The background signal represents the number of green
dots per cell obtained with sense riboprobe. Cells hybridized with
sense riboprobe exhibited no or 1 to 3 green dots as background
signal. Cells showing the same number of green dots as obtained
with the sense riboprobe are considered negative.
FceRI in Neutrophils
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This was performed by incubating the slides with universal
blocking solution (DAKO Diagnostics Canada Inc., Mississauga,
ON)for20 minatRT,followedbyovernightincubation at 4uCwith
mAb-CRA1 or isotype control mAb IgG2a (both at 10 mg/ml)
prepared in antibody diluting buffer (DAKO Cytomation, Ca). The
slides were washed in TBS and incubated with 1:100 dilution of
FITC conjugated affinity pure rat anti-mouse IgG (H+L). Nuclear
counterstaining and image acquisition was performed as described
above. FluoVIEW 2.0 software (Olympus America Inc., Melville,
NY) was used to acquire and analyze the confocal images.
RNA isolation and Real time RT-PCR
Total cellular RNA was extracted using Trizol (Invitrogen).
Reverse transcription (RT) was performed by using 2 mg of total
RNA in a first strand cDNA synthesis reaction with SuperScript
reverse transcriptase as recommended by the supplier (Invitrogen).
The quantification of mRNA of FceRI-a chain expressed by
neutrophils was performed using Real-Time RT-PCR by the Light
Cycler
TM . Primer set for FceRI a chain were: 59CTCCATTA-
CAAATGCCACAGT39and 59CACGCGGAGCTTTTATTA-
CAGTA39. Primers for house-keeping gene glyceraldhyde-3-
phosphate dehydrogenase (GAPDH), and standard controls were
developed in our laboratory. The forward and reverse specific
primer sequences used, the size of the amplified fragment and the
annealing temperature for GAPDH are: 59-AGCAATGCCTC-
CTGCACCACCAAC-39 and 59-CCGGAGGGGCCATCCA-
CAGTCT-39, 137 bp, 59uC. DNA standards were prepared from
PCR using cDNA from cells stimulated by IL-1b. PCR products
were isolated from 0.5% w/v agarose gel using QIAEX II Agarose
Gel Extraction kit (Qiagen). The amount of extracted DNA was
quantified by spectrophotometry and expressed as copy number.
A serial dilution was used to generate each standard curve. PCR
was performed by LightCycler-DNA Master SYBR Green I as
ready to use reaction mix (Roche). Calculation of the amount of
each cDNA species was performed according to manufacturer’s
standard protocol. Briefly, the amplification of target genes in
stimulated cells was calculated by normalizing to the amplification
of GADPH gene in the sample.
Immunoprecipitation and Western blot
For protein extraction, neutrophils were lysed for 30 min at 4uC
in NP-40 lysis buffer supplemented with a cocktail of protease
inhibitors (2mM sodium orthovanadate, 1mM phenyl-methylsul-
fonylfluoride, 10 mg/ml leupeptin, 0.15 units/ml approtinin,
1 mg/ml pepstatin A) (Sigma) and centrifuged for 20 min to
remove nuclei. Cell lysates from neutrophils or basophilic cell line
(KU812, ATCCH # CRL-2099
TM) used as positive control were
sequentially incubated with 2 mg/ml of human IgE (Diateck, Oslo,
Norway) for 16 h at 4uC in a rotating mixer, followed by protein G
sepharose-coated beads (Amersham-Pharmacia) conjugated with
mouse mAb anti-human IgE (Pharmingen) for 2h at 4uC.
Immuno-complexes were pelleted by centrifugation and washed
six times with the wash buffer (PBS /1% NP40). For immuno-
blotting, samples were separated on SDS polyacrylamide gel (13%)
and electro-transferred onto PVDF membrane (Millipore, Mis-
sisauga, Ontario). The membrane was blocked at RT for 2 hrs
with 5% Blotto, (Santa Cruz Biotechnology, CA, USA), incubated
with mouse anti-FceRI-a chain mAbCRA-1 (1 mg/ml) at room
temperature for 2 h, followed by secondary antibody HRP-goat
anti-mouse IgG (H+L) prepared in TBST (1:5000). The blots were
developed by enhanced chemiluminiscence as recommended by
the supplier (Amersham Pharmacia,ON ).
Statistics
Statistical analysis was performed using GraphPad Prism
Software Version 3?02 for Windows (GraphPad Software, San
Diego, CA, USA). The association between levels of FceRI
expression during and out of allergic season was determined by
Wilcoxon signed rank test (paired, non parametric). Association
between expression levels in the subgroups and cytokine
stimulation effect on FceRI expression were studied using Mann-
Whitney U test (unpaired non parametric).
Supporting Information
Figure S1 The effect of IgE on FcRI-a chain expression in
neutrophils. Basophilic cell line (KU8112) and neutrophils from
allergic asthmatics (n=11) were stimulated or not with IgE (10mg/
ml) for 24h. FcRI expression was analyzed by FACS. B-FcRI a
chain antigen surface expression in human neutrophils and human
basophilic cell line tested with quantitative indirect immunofluo-
rescence test.
Found at: doi:10.1371/journal.pone.0001921.s001 (0.58 MB TIF)
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